Influence of escitalopram on somatosensory processing in patients with major depression.

Trial Profile

Influence of escitalopram on somatosensory processing in patients with major depression.

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 16 Apr 2015

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Most Recent Events

    • 13 Apr 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov
    • 01 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Planned end date changed from Dec 2009 to Dec 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top